Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex | Zendy

Lisa M. Shah | Zendy; Michelle S DeStefano | Zendy; Michael H. Cynamon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex

Author(s) -

Lisa M. Shah,

Michelle S DeStefano,

Michael H. Cynamon

Publication year - 1996

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.40.11.2644

Subject(s) - dapsone , in vitro , microbiology and biotechnology , dihydrofolate reductase , minimum inhibitory concentration , mycobacterium avium intracellulare infection , microgram , chemistry , mycobacterium , biology , pharmacology , bacteria , enzyme , biochemistry , immunology , genetics

WR99210, a dihydrofolate reductase inhibitor, has promising in vitro activity against Mycobacterium avium complex (MAC). The in vitro activities of WR99210 alone and in combination with a fixed concentration of dapsone (0.5 microgram/ml) were evaluated against 35 clinical MAC isolates by a broth dilution method. The MIC at which 50% of isolates were inhibited (MIC50) and MIC90 of WR99210 alone were 2 and 8 micrograms/ml, respectively. The MIC50 and MIC90 of WR99210 in combination with dapsone were 0.25 and 4 micrograms/ml, respectively. Overall, 75% of the MAC isolates displayed enhanced susceptibility to the combination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research